---
title: HUB presents data at the 2025 Annual AACR Meeting
description: "Connect with HUB at AACR 2025: Visit our booth 1560, explore our latest scientific posters, and engage with our captivating spotlight talks."
image: https://resources.huborganoids.nl/hubfs/assets2024/aacr-exhibitor.png
---

[![Logo HUB Organoids](https://resources.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "Logo HUB Organoids")](https://huborganoids.nl/)

![merk-m-logo-blue](https://resources.huborganoids.nl/hs-fs/hubfs/merk-m-logo-blue.png?width=728&height=225&name=merk-m-logo-blue.png)

# Meet HUB Organoids at AACR Annual Meeting 2025

Booth #1560

April 25 - 30, 2025  
McCormick Place Convention Center  
Chicago, IL

![](https://resources.huborganoids.nl/hs-fs/hubfs/assets2024/aacr-exhibitor.png?width=300&name=aacr-exhibitor.png)

### Request a meeting

**Advancing Oncology Drug Development with Patient-Derived Organoids**

Join **HUB Organoids** at **AACR 2025**, where we will be showcasing cutting-edge research on **patient-derived organoid models** as transformative tools for oncology drug development. Our posters highlight the latest advancements in **ADC efficacy assessment**, **KRAS inhibitor screening**, and **mechanisms of drug tolerance**, demonstrating the power of organoids in modeling patient-specific treatment responses. Additionally, we present a comparative analysis of **ATP-based vs. image-based viability readouts**, providing insights into optimizing *in vitro* drug screening. Visit our posters to explore how HUB Organoids’ platforms enhance preclinical precision oncology and accelerate the development of targeted cancer therapies.

### Discover our Science

30 April 2025

![listing-img](https://resources.huborganoids.nl/hs-fs/hubfs/listing-img.png?width=221&height=161&name=listing-img.png)

 POSTER PRESENTATION

#### Using a Basket of Patient-Derived Organoids to Identify the Most Promising Cancer Indications for Antibody-Drug Conjugate Development

 Abstract #6743, Presented on 30 April 2025 at 9:00AM - 12:00PM

29 April 2025

![listing-img](https://resources.huborganoids.nl/hs-fs/hubfs/listing-img.png?width=221&height=161&name=listing-img.png)

 POSTER PRESENTATION

#### Comparing ATP-Based and Image-Based Viability Readouts for Assessing Treatment Responses in Patient-Derived Organoids

 Abstract #3994, Presented on 29 April 2025 at 9:00AM - 12:00PM

![listing-img](https://resources.huborganoids.nl/hs-fs/hubfs/listing-img.png?width=221&height=161&name=listing-img.png)

 POSTER PRESENTATION

#### A Patient-derived Organoid Screening Platform as a Powerful Tool to Study Efficacy of KRAS Inhibitors

 Abstract #5706, Presented on 29 April 2025 at 2:00PM - 5:00PM

![listing-img](https://resources.huborganoids.nl/hs-fs/hubfs/listing-img.png?width=221&height=161&name=listing-img.png)

 POSTER PRESENTATION

#### From persistence to resistance: Insights into the mechanisms of drug tolerance in cancer therapy using patient-derived organoids

 Abstract #5551, Presented on 29 April 2025 at 2:00PM - 5:00PM

request a meeting

![Logo HUB Organoids](https://resources.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "Logo HUB Organoids")

[Privacy Policy](https://huborganoids.nl/privacy-policy)

HUB Organoids is now part of the Life Science Business of Merck KGaA, Darmstadt, Germany

***FOR RESEARCH USE ONLY.**  Unless otherwise stated in our catalog or other company documentation  
 accompanying the product(s), our products are intended for research use only and are not to be used   
 for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro   
 diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to   
humans or animals.*